BUFFALO, N.Y., Dec. 16, 2022 (GLOBE NEWSWIRE) — Athenex, Inc. (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced the exit of its 503B sterile compounding business. 503B product sales accounted for approximately 19% of Athenex’s total product sales in the third quarter of 2022.
$1000 Invested In This Stock 10 Years Ago Would Be Worth $6,200 Today
NXP Semiconductors (NASDAQ:NXPI) has outperformed the market over the past 10 years by 9.84% on an annualized basis producing an average annual return of 20.39%. Currently, NXP Semiconductors has a market capitalization of $40.55 billion.
